PAVmed (NASDAQ:PAVM) Price Target Lowered to $1.50 at Lake Street Capital

PAVmed (NASDAQ:PAVMGet Rating) had its target price cut by Lake Street Capital from $5.00 to $1.50 in a research note released on Wednesday, The Fly reports. They currently have a buy rating on the stock.

Separately, Ascendiant Capital Markets set a $8.25 price target on PAVmed in a research note on Thursday, November 24th.

PAVmed Price Performance

Shares of PAVM stock opened at $0.46 on Wednesday. The stock has a market capitalization of $41.49 million, a PE ratio of -0.47 and a beta of 0.79. PAVmed has a 52-week low of $0.40 and a 52-week high of $2.34. The stock’s 50-day moving average price is $0.61 and its 200 day moving average price is $0.99.

PAVmed (NASDAQ:PAVMGet Rating) last released its earnings results on Tuesday, November 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $0.08 million during the quarter. Analysts expect that PAVmed will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling at PAVmed

In other news, Director Michael J. Glennon acquired 62,000 shares of the company’s stock in a transaction dated Monday, December 5th. The stock was acquired at an average cost of $0.69 per share, for a total transaction of $42,780.00. Following the acquisition, the director now directly owns 62,000 shares in the company, valued at approximately $42,780. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Michael J. Glennon purchased 100,000 shares of the stock in a transaction that occurred on Wednesday, December 7th. The stock was purchased at an average cost of $0.62 per share, for a total transaction of $62,000.00. Following the acquisition, the director now owns 250,000 shares in the company, valued at $155,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael J. Glennon purchased 62,000 shares of the stock in a transaction that occurred on Monday, December 5th. The stock was bought at an average price of $0.69 per share, with a total value of $42,780.00. Following the completion of the acquisition, the director now owns 62,000 shares in the company, valued at approximately $42,780. The disclosure for this purchase can be found here. 14.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On PAVmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of PAVmed during the second quarter worth about $1,483,000. Vanguard Group Inc. lifted its holdings in PAVmed by 6.8% in the third quarter. Vanguard Group Inc. now owns 3,700,905 shares of the company’s stock worth $3,182,000 after acquiring an additional 236,448 shares during the last quarter. Verition Fund Management LLC bought a new position in PAVmed in the first quarter worth about $196,000. State Street Corp lifted its holdings in PAVmed by 8.8% in the first quarter. State Street Corp now owns 1,496,536 shares of the company’s stock worth $1,975,000 after acquiring an additional 120,691 shares during the last quarter. Finally, Lido Advisors LLC lifted its holdings in PAVmed by 400.0% in the first quarter. Lido Advisors LLC now owns 50,000 shares of the company’s stock worth $66,000 after acquiring an additional 40,000 shares during the last quarter. 13.98% of the stock is owned by hedge funds and other institutional investors.

PAVmed Company Profile

(Get Rating)

PAVmed, Inc is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes.

Featured Stories

The Fly logo

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.